Citations

Showing 10 of 108094 citations.

Vomer‐Rostrum Mucosal Flap for Exposed Bone Coverage After Sphenoid Sinusotomy
Goates, Andrew J. , Pinheiro‐Neto, Carlos , Choby, Garret , Pinheiro-Neto, Carlos D , Choby, Garret

Mayo Clinic

The Laryngoscope | June 29, 2022 | Volume: 133 | Issue: 3 | Pages: 552-556

10.1002/lary.30268 | PMID 35766378 Get It

Emergency medicine physician supervision and mortality among patients receiving care from non-physician clinicians in a task-sharing model of emergency care in rural Uganda: a retrospective analysis of a single-centre training programme
Rice, Brian , Pickering, Ashley , Laurence, Colleen , Kizito, Prisca Mary , Leff, Rebecca , Kisingiri, Steven Jonathan, Ndyamwijuka, Charles, Nakato, Serena, Adriko, Lema Felix, Bisanzo, Mark

Mayo Clinic

BMJ Open | June 29, 2022 | Volume: 12 | Issue: 6 | Pages: e059859

10.1136/bmjopen-2021-059859 | PMID 35768107 Get It

Objectives To assess the association between emergency medicine physician supervision and 3-day mortality for patients receiving care from non-physician clinicians in a task-sharing model of emergency care in rural Uganda. Design Retrospective cohort analysis with multivariable logistic regression. Setting Single rural Ugandan emergency unit. Participants All patients presenting for care from 2009 to 2019. Interventions Three cohorts of patients receiving care from non-physician clinicians had three different levels of physician supervision: ‘Direct Supervision’ (2009–2010) emergency medicine physicians directly supervised all care; ‘Indirect Supervision’ (2010–2015) emergency medicine physicians were consulted as needed; ‘Independent Care’ (2015–2019) no emergency medicine physician supervision. Primary outcome measure Three-day mortality. Results 38 033 ED visits met inclusion criteria. Overall mortality decreased significantly across supervision cohorts (‘Direct’ 3.8%, ‘Indirect’ 3.3%, ‘Independent’ 2.6%, p<0.001), but so too did the rates of patients who presented with ≥3 abnormal vitals (‘Direct’ 32%, ‘Indirect’ 19%, ‘Independent’ 13%, p<0.001). After controlling for vital sign abnormalities, ‘Direct’ and ‘Indirect’ supervision were both significantly associated with reduced OR for mortality (‘Direct’: 0.57 (0.37 to 0.90), ‘Indirect’: 0.71 (0.55 to 0.92)) when compared with ‘Independent Care’. Sensitivity analysis showed that this mortality benefit was significant for the minority of patients (17.2%) with ≥3 abnormal vitals (‘Direct’: 0.44 (0.22 to 0.85), ‘Indirect’: 0.60 (0.41 to 0.88)), but not for the majority (82.8%) with two or fewer abnormal vitals (‘Direct’: 0.81 (0.44 to 1.49), ‘Indirect’: 0.82 (0.58 to 1.16)). Conclusions Emergency medicine physician supervision of emergency care non-physician clinicians is independently associated with reduced overall mortality. This benefit appears restricted to the highest risk patients based on abnormal vitals. With over 80% of patients having equivalent mortality outcomes with independent non-physician clinician emergency care, a synergistic model providing variable levels of emergency medicine physician supervision or care based on patient acuity could safely address staffing shortages.
Prothrombin Complex Concentrate vs Plasma for Post–Cardiopulmonary Bypass Coagulopathy and Bleeding
Schroeder, Darrell R. , Nelson, James A. , Mauermann, William J., Pochettino, Alberto , Montonye, Beth L., Assawakawintip, Chalailak, Nuttall, Gregory A. , Schroeder, Darrell , Smith, Mark M. , Nelson, James A., Welsby, Ian J

Mayo Clinic

JAMA Surgery | June 29, 2022 | Volume: 157 | Issue: 9 | Pages: 757

10.1001/jamasurg.2022.2235 | PMID 35767271 Get It

Improvement of Facial Discoid Dermatosis With Ustekinumab Treatment
Rypka, Katelyn , Fulk, Travis, Afsaneh, Alavi, Miller, Daniel D. , Goldfarb, Noah

Mayo Clinic

JAMA Dermatology | June 29, 2022 | Volume: 158 | Issue: 9 | Pages: 1079

10.1001/jamadermatol.2022.2478 | PMID 35767241 Get It

This case report describes a woman in her early 40s with a 10-year history of facial rash; multiple well-demarcated, orangish-pink, flat-topped papules; and plaques with fine scale that involved the forehead, cheeks, jawline, and neck.
Faculty Opinions recommendation of Hypothesis: why different types of SDH gene variants cause divergent tumor phenotypes.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742209677.793593853 Get It

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise
Yoon, Harry H. , Dong, Haidong , Shi, Qian , Shi, Qian , Dong, Haidong

Mayo Clinic

Clinical Cancer Research | June 29, 2022 | Volume: 28 | Issue: 15 | Pages: 3173-3175

10.1158/1078-0432.ccr-22-0932 | PMID 35671005 Get It

Summary Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277
Impact of Managing Provider Type on Severe Aortic Stenosis Management and Mortality
Pellikka, Patricia A. , Padang, Ratnasari , Scott, Christopher G. , Murphy, Shannon , Fabunmi, Rosalind P., Thaden, Jeremy J. , Murphy, Shannon M E , Scott, Christopher , Pellikka, Patricia A

Mayo Clinic

Journal of the American Heart Association | June 29, 2022 | Volume: 11 | Issue: 13 | Pages: No page available

10.1161/jaha.121.025164 | PMID 35766279 Get It

Background Many patients with symptomatic severe aortic stenosis do not undergo aortic valve replacement (AVR) despite clinical guidelines. This study analyzed the association of managing provider type with cardiac specialist follow‐up, AVR, and mortality for patients with newly diagnosed severe aortic stenosis (sAS). Methods and Results We identified adults with newly diagnosed sAS per echocardiography performed between January 2017 and March 2019 using Optum electronic health record data. We then selected from those meeting all eligibility criteria patients managed by a primary care provider (n=1707 [25%]) or cardiac specialist (n=5039 [75%]). We evaluated the association of managing provider type with cardiac specialist follow‐up, AVR, and mortality, as well as the independent association of cardiac specialist follow‐up and AVR with mortality, within 1 year of echocardiography detecting sAS. A subgroup analysis was limited to patients with symptomatic sAS. Patient characteristics and comorbidities at baseline were used for covariate‐adjusted cause‐specific and multivariable Cox proportional hazard models assessing group differences in outcomes by managing provider type. An adjusted Cox proportional hazard model with additional time‐dependent covariates for follow‐up and AVR was used to assess these practices' association with mortality. Within 1 year of echocardiography detecting sAS, data revealed that primary care provider management was associated with lower rates of cardiac specialist follow‐up (hazard ratio [HR], 0.47 [95% CI, 0.43–0.50], P <0.0001) and AVR (HR, 0.58 [95% CI, 0.53–0.64], P <0.0001) and with higher 1‐year mortality (HR, 1.45 [95% CI, 1.26–1.66], P <0.0001). Cardiac specialist follow‐up and AVR were independently associated with lower mortality (follow‐up: HR, 0.55 [95% CI, 0.48–0.63], P <0.0001; AVR: HR, 0.70 [95% CI, 0.60–0.83], P <0.0001). Results were similar for patients with symptomatic sAS. All analyses were adjusted for baseline patient characteristics and comorbidities. Conclusions For patients newly diagnosed with sAS, we observed differences in rates of cardiac specialist follow‐up and AVR and risk of mortality between primary care provider‐ versus cardiologist‐managed patients with sAS. In addition, a lower likelihood of receiving follow‐up and AVR was independently associated with higher mortality.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Li, Yan , Taddei, Kevin , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Fagan, Anne M. , Gordon, Brian A , Vermunt, Lisa , Pedrini, Steve , Singh, Abhay Kumar , Sohrabi, Hamid R. , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John C. , Karch, Celeste M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Lee, Jae‐Hong , Xiong, Chengjie , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v1 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
Differential migration mechanics and immune responses of glioblastoma subtypes
Shamsan, Ghaidan A. , Liu, Chao J. , Braman, Brooke C , Li, Ruyi , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima, McMahon, Mariah, Klank, Rebecca, McFarren, S. Joey, Rosato, Pamela C. , Sarkaria, Jann N., Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , McMahon, Mariah , Shamsan, Ghaidan A , Rosato, Pamela C , Liu, Chao J. , Rathe, Susan K. , Klank, Rebecca L. , Tschida, Barbara R , McFarren, S Joseph. , Masopust, David , Sarkaria, Jann N., Largaespada, David A. , Odde, David J

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.06.26.497270 Get It

Abstract Glioblastoma remains a deadly cancer driven in part by invasion of tumor cells into the brain. Transcriptomic analyses have identified distinct molecular subtypes, but mechanistic differences that account for clinical differences are not clear. Here, we show that, as predicted by the motor-clutch model of cell migration, mesenchymal glioma cells are more spread, generate larger traction forces, and migrate faster in brain tissue compared to proneural cells. Despite their rapid migration and comparable proliferation rates in vitro, mice with mesenchymal tumors survive longer than those with proneural tumors. This improved survival correlated with an immune response in the mesenchymal tumors, including T cell-mediated. Consistently, inducing mesenchymal tumors in immunodeficient mice resulted in shorter survival supporting a protective immune role in mesenchymal tumors. Thus, mesenchymal tumors have aggressive migration, but are immunologically ‘hot’ which suppresses net proliferation. These two features counteract each other and may explain the lack of a strong survival difference between subtypes clinically, while also opening up new opportunities for subtype-specific therapies. Significant Statement This study highlights new mechanical and immunological insights into glioblastoma molecular subtypes using an integrated modeling-genome engineering strategy, which can potentially facilitate glioblastoma subtype-specific therapeutic strategies.
The publication impact of the first 100 THOR Network publications by bibliometric and social network analyses
Woolley, Tom , Stubbs, James R. , Sprague, Evan R. , Suiter, Amy M. , Sarli, Cathy , Strandenes, Geir , Spinella, Philip C. , Sprague, Evan , Sarli, Cathy C , Strandenes, Geir , Spinella, Philip C

Mayo Clinic

Transfusion | June 29, 2022 | Volume: 62 | Issue: S1 | Pages: No page available

10.1111/trf.16956 | PMID 35765971 Get It

AbstractBackgroundA specialized international multidisciplinary group of investigators wanted to determine the performance and impact of publications presented at an annual conference over a 6 year period. Specifically, the group wanted to know if the influence of the conference publications extended beyond conference publication authors and attendees. Bibliometric methods and network analyses were used to evaluate the performance and impact of 100 peer‐reviewed publications presented at the Trauma Hemostasis and Oxygenation Research (THOR) Network Remote Damage Control Resuscitation (RCDR) Symposia from 2012 to 2017 (published 2013–2018). Further analysis was performed on the affiliations of conference attendees who attended from the years of 2012 to 2017.Study Design and MethodsThis project used normative and relative bibliometric measures and social network analysis to evaluate the performance and impact of 100 peer‐reviewed publications presented at the Trauma Hemostasis and Oxygenation Research (THOR) Network RDCR Symposia from 2012 to 2017. Publication and citation data were from Elsevier Scopus, a bibliographic citation database. Metrics from Elsevier SciVal were selected for the project to normalize for group size, year of publication, and document type. A six‐year period of publications presented at the Symposia, published from 2013 to 2018, was selected for analysis. The publication and citation data were further analyzed using Elsevier SciVal and the iCite database from the National Institutes of Health Office of Portfolio Analysis. Sci2, VOSviewer, and Gephi were used for social network analyses and visualization.ResultsThe 100 publications presented at the Trauma Hemostasis and Oxygenation Research (THOR) Network Remote Damage Control Resuscitation (RCDR) Symposia from 2012 to 2017 demonstrate reach and influence beyond the authors of the THOR publications or the THOR attendees. Citations to the THOR publications were published in 10 languages and 313 unique journals, with author affiliations from 62 countries. Citation metrics for the THOR publications exceed global averages with 65% of the THOR publications being in the 25% citation percentiles. When benchmarking the THOR publications using six homogenous comparator groups, the THOR publications demonstrate higher citation metrics than any of the comparator groups with more citations per publication, a higher average of cited publications, higher FWCI and outputs in the top citation percentiles among the six groups. The Office of Portfolio Analysis (OPA) iCite database was used to calculate potential to translate for the THOR publications with 57 of the THOR publications cited by clinical articles with an average approximate potential to translate score of 65.3%.ConclusionsThe value of international groups with sharing of research and knowledge are instrumental in enhancing the uptake for best practices for in medicine and treatment of hemorrhagic shock resuscitation. The use of bibliometric methods and network analyses, along with benchmarking, demonstrated reach and impact beyond the THOR Network. Limitations include use of a single source for analysis of publication and citation; and that publication data alone does not provide a full overview of research performance. Despite these limitations, bibliometric methods, social network analyses, and benchmarking can help centers better understand their impact.